药物研发外包的全球市场 (2022-2028年):药物类型·工作流程·治疗领域·各用途的规模·占有率·成长分析·预测

Global Drug Discovery Outsourcing Market Size, Share, Growth Analysis, By Drug Type, By Workflow, By Therapeutic area, By Application - Industry Forecast 2022-2028

出版日期: 2023年04月30日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

药物研发外包的市场规模在2021年估算为32亿6,000万美元，2022年35亿美元，在2023年到2030年的预测期间中预计将以7.3％的年复合成长率推移，到2030年达到62亿美元的规模。

公共机构和私营公司之间的合作正在取得进展，加快了药物发现过程，全球对药物发现外包服务的需求正在增加。此外，製药和生物製药行业研发费用的增加、对分析测试服务的需求增加、罕见病和孤儿药研究的举措以及高昂的内部药物开发成本正在为药物发现服务市场创造新的收入来源。

本报告提供全球药物研发外包的市场调查，彙整市场概要，市场的各种影响因素的分析，技术·革新趋势，市场规模的转变·预测，各种区分·各地区的明细，竞争情形，主要企业简介等资讯。

市场概要
市场规模
市场动态
促进因素
机会
阻碍因素
课题
主要市场洞察
技术分析
价格分析
供应链分析
价值链分析
市场生态系统
IP分析
贸易分析
Start-Ups分析
原料分析
革新矩阵
开发中产品的分析
宏观经济指标
主要投资分析
主要成功因素
竞争的程度
市场动态及预测
市场动态
促进因素
机会
阻碍因素
课题
法规情形
波特分析
未来的阻碍相关Skyquest的特别见解
全球药物研发外包市场:药物各类型
- 市场概要
- 低分子
- 高分子
- 生技药品
全球药物研发外包市场:工作流程
- 市场概要
- 目标的鑑定·筛检
- 目标的验证·功能性资讯学
- 领导的特定·候补的最佳化
- 前临床开发
- 其他
全球药物研发外包市场:各治疗领域
- 市场概要
- 呼吸系统
- 肿瘤
- 眼科
- 血液
- 心血管系统
- 内分泌
- 肠胃
- 免疫调节
- 抗感染疾病
- 中枢神经系统
- 皮肤科
- 泌尿器官系统
全球药物研发外包市场:各用途
- 市场概要
- 医院·诊疗所
- 医疗实验室
- 其他
全球药物研发外包市场:各地区
- 市场概要
- 北美
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他的欧洲地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他的亚太地区
- 南美
- 巴西
- 其他的南美地区
- 中东·非洲
- GCC各国
- 南非
- 其他的中东·非洲地区
竞争情形
前五名公司的比较
主要企业的地位
主要企业的招聘策略
主要成功策略
市场上最近的活动
主要企业的市场占有率
主要企业简介
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
WuXi AppTec Co., Ltd.
Albany Molecular Research Inc. (AMRI)
GVK Biosciences Private Limited
Sygnature Discovery
Pharmaron Beijing Co., Ltd
WuXi Biologics (Cayman), Inc.
Domainex Ltd.
Thermo Fisher Scientific, Inc.
Jubilant Biosys Ltd.
Evotec SE
Eurofins Discovery
GenScript Biotech Corporation

简介目录

Product Code: SQMIG35C2011

Global Drug Discovery Outsourcing Market size was valued at USD 3.26 billion in 2021 and is poised to grow from USD 3.5 billion in 2022 to USD 6.2 billion by 2030, growing at a CAGR of 7.3% in the forecast period (2023-2030).

Rising collaborations between public and commercial entities speed up drug discovery procedures, increasing global demand for drug discovery outsourcing services. The ultimate goal of a preclinical drug discovery programme is to deliver one or more clinical candidate molecules that have sufficient evidence of biological activity at a disease-relevant target as well as sufficient safety and drug-like properties to be tested in humans.

Growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, rising demand for analytical testing services, initiatives for rare disease and orphan drug research, and the high cost of in-house drug development are all creating new revenue pockets in the drug discovery services market.

Many pharmaceutical and biotechnology businesses partnered with CROs through long-term agreements, partnerships, and collaborations around the world to accelerate the R&D process. Eurofins Scientific SE (France), for example, launched Adaptive immune response models in May 2021 to study the immunological repercussions of SARS-CoV-2 and other viral diseases for drug discovery.

Top-down and bottom-up approaches were used to estimate and validate the size of global Drug Discovery Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Segments covered in this report

Global Drug Discovery Outsourcing Market is segmented on the basis of drug type, workflow, therapeutic area, application, and region. By drug type, the Drug Discovery Outsourcing Market is segmented into small molecule, large molecule, and biologics. By workflow, the Drug Discovery Outsourcing Market is segmented into Target Identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, the Drug Discovery Outsourcing Market is segmented into Respiratory system, oncology, ophthalmology, haematology, cardiovascular, endocrine, gastrointestinal, immunomodulation, anti-infective, central nervous system, dermatology, and genitourinary system. By application, the Drug Discovery Outsourcing Market is segmented into Hospitals & clinics, medical laboratories, and others. By region, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

Drivers

Increased investment in healthcare infrastructure development will create lucrative opportunities for the global drug discovery outsourcing market.

Pharmaceutical and biopharmaceutical businesses' increasing R&D expenditures are leading them to seek fully integrated or functional outsourcing services for drug research and development, from the early development stage to the late-stage development phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources required for new product development as pharma businesses face great pressure to limit fixed costs. Large pharmaceutical corporations are shifting to a leaner business strategy that mainly relies on outsourcing. Most pharmaceutical and biopharmaceutical businesses outsource their testing services throughout R&D to increase profitability, meet drug development timeframes, and save money. This is evidenced by major pharmaceutical companies' recent deals with CROs that provide drug discovery and development services. As a result, rising pharmaceutical R&D spending fuels the growth of the drug discovery services industry.

Restraint

Stringent policies and high manufacturing costs will stymie the growth of the drug delivery outsourcing market.

The primary focus of regulatory bodies during drug approval is ensuring safety and efficacy, which significantly raises the cost of drug development and the final product. This aspect can have a substantial impact on medicine uptake in price-sensitive emerging markets. Aside from that, different legislations that protect product quality (such as GMP) frequently raise manufacturing prices. Animal testing in drug discovery is governed by strict restrictions. The most regularly employed animals in study are mice, rats, fish, amphibians, and reptiles. Concerns about the ethical use of animals in research have prompted governments to enact animal safety and use legislation, which poses various hurdles to the smooth operation of drug discovery research. Companies have been obliged to find alternative methods to reduce animal use. Novo Nordisk, for example, employs bio simulation, which entails employing computer models to imitate human biology. However, this has not been fully implemented throughout the market.

Market Trends

The escalation of cancer cases will shape the future of the global drug discovery outsourcing market.

As more small and medium-sized businesses outsource drug discovery services, the value chain of the drug discovery outsourcing market will see new growth prospects in the future years.

During the foreseeable period, oncology will lead worldwide demand since the burden of curing cancer remains a global duty.